HIMS

Hims & Hers Health stock fell 8.9% to near $28.84, about 54% below its 52-week high. While the stock typically recovers from market shocks within months, its deepest historical drawdown of 87% (2021-2022) exceeds any sho

Hims & Hers Health shares fell as much as 9.5% on August 21, 2026, after Bloomberg reported that Visa placed the company in its Acquirer Monitoring Program due to a surge in credit card disputes in July, primarily from i

Hims & Hers Health shares fell 14.6% after the company reported strong quarterly results but faced escalating legal and regulatory scrutiny over privacy and billing practices. The telehealth firm posted second-quarter re

Shares of Hims & Hers Health and Novo Nordisk fell after both companies reported rising costs that are eating into profits from the booming GLP-1 weight-loss pill market. Hims & Hers posted Q2 revenue of $753.2 million,

Hims & Hers Health trades at a price-to-sales ratio of 2.8, cheaper than the S&P 500's 3.3, but its operating cash flow multiple of 27.3 is more expensive than the market's 15.5, reflecting a low 10.2% revenue-to-cash co

Hims & Hers CEO Andrew Dudum defended the company against a Federal Trade Commission lawsuit, accusing the agency of seeking "more of a headline than a real agreement" after years of cooperative talks, according to a CNB

Hims & Hers Health is facing a new consumer class action lawsuit alleging it misled users about privacy and shared sensitive health data without authorization. The lawsuit follows a recent FTC civil enforcement action ra

Hims & Hers Health raised its full-year 2026 revenue guidance to $3.2 billion at the midpoint (from $2.9 billion) after Q2 revenues of $753.2 million beat analyst estimates by 7.8%, though a non-GAAP loss of $0.09 per sh